Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2D CAR-T
- Development stage
- Preclinical
- Lead developer
- YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
NKG2D CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by YaKe Biotechnology for the treatment of various solid tumors. The therapy consists of autologous T cells genetically engineered to express a CAR based on the natural killer group 2 member D (NKG2D) receptor. This receptor recognizes NKG2D ligands (NKG2DL), which include stress-induced proteins such as MHC class I polypeptide-related sequence A (MICA), MHC class I polypeptide-related sequence B (MICB), and the UL16-binding protein (ULBP) family. These ligands are frequently upregulated on the surface of tumor cells in response to oncogenic transformation or cellular stress but have limited expression on healthy tissues. Upon binding to these ligands, the CAR-T cells mediate direct cytotoxicity to eliminate the cancer cells. The product is currently in the preclinical stage of development.
- Other names
- NKG2D CAR T-cellNKG-2D CAR T-cellNKG 2D CAR T-cellCAR-T NKG2D ligands
02
Targets
RAET1E (UL16-binding protein 4)MICA (Major histocompatibility complex class I-related protein A)ULBP1 (UL16-binding protein 1)ULBP2 (UL16-binding protein 2)ULBP6 (UL16-binding protein 6)ULBP5 (UL16-binding protein 5)ULBP3 (UL16 binding protein 3)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on NKG2D CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2D CAR-T.